{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T16:38:45Z","timestamp":1782232725744,"version":"3.54.5"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["brachyjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brachytherapy"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.brachy.2015.01.004","type":"journal-article","created":{"date-parts":[[2015,2,28]],"date-time":"2015-02-28T15:49:00Z","timestamp":1425138540000},"page":"359-365","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["High-dose-rate brachytherapy as a monotherapy for prostate cancer\u2014Single-institution results of the extreme fractionation regimen"],"prefix":"10.1016","volume":"14","author":[{"given":"Andrzej Marek","family":"Kukie\u0142ka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"D\u0105browski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Walasek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Olchawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roksana","family":"Kudzia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Dybek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.brachy.2015.01.004_bib1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.5114\/jcb.2013.34342","article-title":"Low-dose-rate or high-dose-rate brachytherapy in treatment of prostate cancer\u2014between options","volume":"5","author":"Skowronek","year":"2013","journal-title":"J Contemp Brachytherapy"},{"key":"10.1016\/j.brachy.2015.01.004_bib2","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.brachy.2014.03.002","article-title":"High-dose-rate as monotherapy for prostate cancer","volume":"13","author":"Demanes","year":"2014","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2015.01.004_bib3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.5114\/jcb.2014.42026","article-title":"High-dose-rate brachytherapy as monotherapy for prostate cancer: Technique, rationale and perspective","volume":"6","author":"Yoshioka","year":"2014","journal-title":"J Contemp Brachytherapy"},{"key":"10.1016\/j.brachy.2015.01.004_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2005.06.009","article-title":"The \u03b1\/\u03b2 ratio for prostate cancer: What is it, really?","volume":"76","author":"Bentzen","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2015.01.004_bib5","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.radonc.2011.07.017","article-title":"Long-term biochemical control of prostate cancer after standard or hyper-fractionation: Evidence for different outcomes between low-intermediate and high risk patients","volume":"101","author":"Valdagni","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2015.01.004_bib6","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.ijrobp.2004.07.723","article-title":"Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy","volume":"61","author":"Cheung","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2015.01.004_bib7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0360-3016(01)01758-8","article-title":"Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer","volume":"52","author":"Galalae","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2015.01.004_bib8","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Prostate cancer, Version 2.2014. NCCN; 2014. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf. Accessed December 2014."},{"key":"10.1016\/j.brachy.2015.01.004_bib9","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.brachy.2011.09.008","article-title":"American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy","volume":"11","author":"Yamada","year":"2012","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2015.01.004_bib10","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.radonc.2013.05.002","article-title":"GEC\/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: An update","volume":"107","author":"Hoskin","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2015.01.004_bib11","first-page":"137","article-title":"HDR brachytherapy of prostate cancer\u2014Two years experience in Greater Poland Cancer Centre","volume":"1","author":"Kanikowski","year":"2009","journal-title":"J Contemp Brachytherapy"},{"key":"10.1016\/j.brachy.2015.01.004_bib12","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S1507-1367(05)71098-1","article-title":"Real time brachytherapy for prostate cancer\u2014A new challenge for medical physicists","volume":"10","author":"\u015alosarek","year":"2005","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1016\/j.brachy.2015.01.004_bib13","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE), version 4.0.\u00a0Available at: http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_40. Accessed December 2014."},{"key":"10.1016\/j.brachy.2015.01.004_bib14","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2015.01.004_bib15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.brachy.2008.09.004","article-title":"Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a monotherapy","volume":"8","author":"Ghadjar","year":"2009","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2015.01.004_bib16","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.ijrobp.2011.04.031","article-title":"High-dose-rate brachytherapy alone for localized prostate cancer in patients at moderate or high risk of biochemical recurrence","volume":"82","author":"Hoskin","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2015.01.004_bib17","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/COC.0b013e3181b9cd2f","article-title":"High-dose-rate prostate brachytherapy: An excellent accelerated-hypofractionated treatment for favorable prostate cancer","volume":"33","author":"Martinez","year":"2010","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.brachy.2015.01.004_bib18","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.juro.2011.09.050","article-title":"High dose brachytherapy as monotherapy for intermediate risk prostate cancer","volume":"187","author":"Rogers","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.brachy.2015.01.004_bib19","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/j.ijrobp.2010.09.006","article-title":"High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: A phase II trial","volume":"82","author":"Barkati","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2015.01.004_bib20","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.ijrobp.2012.07.004","article-title":"High-dose-rate interstitial brachytherapy as monotherapy for clinically localized prostate cancer: Treatment evolution and mature results","volume":"85","author":"Zamboglou","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2015.01.004_bib21","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ijrobp.2010.02.013","article-title":"Monotherapeutic high-dose-rate brachytherapy for prostate cancer: Five-year results of an extreme hypofractionation regimen with 54 Gy in nine fractions","volume":"80","author":"Yoshioka","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2015.01.004_bib22","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.ijrobp.2010.10.015","article-title":"High-dose-rate monotherapy: Safe and effective brachytherapy for patients with localized prostate cancer","volume":"81","author":"Demanes","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2015.01.004_bib23","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/1748-717X-9-122","article-title":"Late toxicity and five year outcomes after high-dose-rate brachytherapy as monotherapy for localized prostate cancer","volume":"9","author":"Ghadjar","year":"2014","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.brachy.2015.01.004_bib24","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.radonc.2013.10.015","article-title":"Monotherapeutic high-dose-rate brachytherapy for prostate cancer: A dose reduction trial","volume":"110","author":"Yoshioka","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2015.01.004_bib25","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.radonc.2013.09.025","article-title":"High-dose-rate brachytherapy alone given as two or one fraction to patients for locally advanced prostate cancer: Acute toxicity","volume":"110","author":"Hoskin","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2015.01.004_bib26","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.ijrobp.2011.05.001","article-title":"High-dose-rate brachytherapy as monotherapy delivered in two fractions within one day for favorable\/intermediate-risk prostate cancer: Preliminary toxicity data","volume":"83","author":"Ghilezan","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2015.01.004_bib27","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.brachy.2011.05.003","article-title":"High-dose-rate interstitial brachytherapy as monotherapy in one fraction and transperineal hyaluronic acid injection into the perirectal fat for the treatment of favorable stage prostate cancer: Treatment description and preliminary results","volume":"11","author":"Prada","year":"2012","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2015.01.004_bib28","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.ijrobp.2008.12.051","article-title":"Correlation between dosimetric parameters and late rectal and urinary toxicities in patients treated with high-dose-rate brachytherapy used as monotherapy for prostate cancer","volume":"75","author":"Konishi","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2015.01.004_bib29","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.ijrobp.2004.02.053","article-title":"Dosimetric impact of prostate volume change between CT-based brachytherapy fractions","volume":"59","author":"Kim","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2015.01.004_bib30","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ijrobp.2010.01.016","article-title":"Dosimetric impact of interfraction catheter movement in high-dose rate prostate brachytherapy","volume":"80","author":"Foster","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2015.01.004_bib31","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.radonc.2007.11.004","article-title":"HDR prostate monotherapy\u2014Dosimetric effects of implant deformation due to posture change between TRUS- and CT-imaging","volume":"86","author":"Seppenwoolde","year":"2008","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2015.01.004_bib32","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.urology.2009.01.043","article-title":"Prostate-specific antigen bounce after prostate brachytherapy: Review of a confusing phenomenon","volume":"74","author":"Caloglu","year":"2009","journal-title":"Urology"}],"container-title":["Brachytherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472115000197?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472115000197?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:08:46Z","timestamp":1761530926000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538472115000197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S1538472115000197"],"URL":"https:\/\/doi.org\/10.1016\/j.brachy.2015.01.004","relation":{},"ISSN":["1538-4721"],"issn-type":[{"value":"1538-4721","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-dose-rate brachytherapy as a monotherapy for prostate cancer\u2014Single-institution results of the extreme fractionation regimen","name":"articletitle","label":"Article Title"},{"value":"Brachytherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brachy.2015.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}